Replies to post #4594 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Based upon the two recent setbacks that WYE has endured it would be reasonable to assume they might be very interested in partnering with GTCB.<

Moreover, WYE’s BeneFix brand of rFIX goes off-patent in the US in early 2011 (including the extension pursuant to 35 USC §156).